NO20042011L - Fremgangsmate ved fremstilling av en farmasoytisk sammensetning omfattende 5-aminosalisylsyre for bruk ved behandling av ulcerativ kolitt og Crohns sykdom - Google Patents

Fremgangsmate ved fremstilling av en farmasoytisk sammensetning omfattende 5-aminosalisylsyre for bruk ved behandling av ulcerativ kolitt og Crohns sykdom

Info

Publication number
NO20042011L
NO20042011L NO20042011A NO20042011A NO20042011L NO 20042011 L NO20042011 L NO 20042011L NO 20042011 A NO20042011 A NO 20042011A NO 20042011 A NO20042011 A NO 20042011A NO 20042011 L NO20042011 L NO 20042011L
Authority
NO
Norway
Prior art keywords
crohn
disease
treatment
pharmaceutical composition
ulcerative colitis
Prior art date
Application number
NO20042011A
Other languages
English (en)
Other versions
NO335042B1 (no
Inventor
Svenn Kluever Jepsen
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of NO20042011L publication Critical patent/NO20042011L/no
Publication of NO335042B1 publication Critical patent/NO335042B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Det er beskrevet en ny fremgangsmåte ved fremstilling av granuler omfattende 5-aminosalicylsyre samt en ny fremgangsmåte ved fremstilling av en farmasøytisk sammensetning til behandling av ulcerativ kolitt eller Crohns sykdom ved oral administrasjon, omfattende, som aktiv bestanddel, 5-aminosalisylsyre.
NO20042011A 2001-10-15 2004-05-14 Fremgangsmåte ved fremstilling av en farmasøytisk sammensetning omfattende 5-aminosalisylsyre for bruk ved behandling av ulcerativ kolitt og Crohns sykdom NO335042B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/DK2001/000677 WO2003032952A1 (en) 2001-10-15 2001-10-15 Method for the preparation of a pharmaceutical composition comprising 5-aminosalicyclic acid for use in treatment of ulcerative colitis and crohn's disease

Publications (2)

Publication Number Publication Date
NO20042011L true NO20042011L (no) 2004-06-30
NO335042B1 NO335042B1 (no) 2014-09-01

Family

ID=8149447

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20042011A NO335042B1 (no) 2001-10-15 2004-05-14 Fremgangsmåte ved fremstilling av en farmasøytisk sammensetning omfattende 5-aminosalisylsyre for bruk ved behandling av ulcerativ kolitt og Crohns sykdom

Country Status (14)

Country Link
EP (1) EP1441700B1 (no)
JP (1) JP4726414B2 (no)
KR (1) KR100859358B1 (no)
CN (1) CN100506234C (no)
AT (1) ATE371441T1 (no)
CA (1) CA2462905C (no)
DE (1) DE60130270T2 (no)
DK (1) DK1441700T3 (no)
ES (1) ES2288999T3 (no)
IL (2) IL161193A0 (no)
MX (1) MXPA04003506A (no)
NO (1) NO335042B1 (no)
PT (1) PT1441700E (no)
WO (1) WO2003032952A1 (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070059368A1 (en) * 2005-05-31 2007-03-15 Cherukuri S R Modified release formulations of anti-irritability drugs
CA2520197A1 (en) * 2003-04-23 2004-11-04 Ferring B.V. Sachet for a pharmaceutical composition
EP1470819A1 (en) * 2003-04-23 2004-10-27 Ferring B.V. High drug load mesalazine sachet
EP1547601A1 (en) * 2003-12-23 2005-06-29 Ferring B.V. Coating method
EP1784166B1 (en) * 2004-09-01 2009-03-04 The Procter and Gamble Company Compositions comprising 5-amino-2-hydroxybenzoic acid and a reducing sugar
GB0909680D0 (en) 2009-06-05 2009-07-22 Euro Celtique Sa Dosage form
EP2340812A1 (en) 2009-12-18 2011-07-06 Ferring International Center S.A. Granules for pharmaceutical preparations, methods and apparatus for their production
CA2810283A1 (en) * 2010-09-10 2012-03-15 Pharmazell Gmbh Process for producing crystalline 5-aminosalicylic acid
US10071058B2 (en) * 2012-03-07 2018-09-11 Santarus, Inc. Controlled-release solid dosage forms of mesalamine
CN103622974B (zh) * 2013-12-05 2016-04-20 武汉武药科技有限公司 一种含美沙拉嗪和n-乙酰半胱氨酸的复方栓剂及其制备方法
US20170143743A1 (en) * 2014-06-16 2017-05-25 Valpharma International S.P.A. Formulation for oral administration containing mesalazine
ITUA20162293A1 (it) 2016-04-05 2017-10-05 Sofar Spa Processo per formulazioni solide di mesalazina
JP2017189121A (ja) * 2016-04-11 2017-10-19 国立大学法人旭川医科大学 抗ＴＮＦα抗体適応疾患の治療における抗ＴＮＦα抗体投与時反応の発症リスクを判定する方法、並びに該判定用オリゴヌクレオチドキット

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1981002671A1 (en) * 1980-03-20 1981-10-01 Ferring Farma Lab Pharmaceutical composition and method for the treatment of colitis ulcerosa and crohn's disease by oral administration
JPH0334928A (ja) * 1989-06-29 1991-02-14 Teikoku Seiyaku Kk 潰瘍性大腸炎およびクローン病治療用経口投与製剤
AU702934B2 (en) * 1995-12-21 1999-03-11 Farmaceutisk Laboratorium Ferring A/S Modified release oral pharmaceutical composition containing 5-asa and method for the treatment of bowel diseases
IT1303753B1 (it) * 1998-11-13 2001-02-23 Ct Lab Farm Srl Composizioni farmaceutiche somministrabili per via orale contenentiun rivestimento gastroresistente a base di polimeri acrilici.
IT1318625B1 (it) * 2000-07-14 2003-08-27 Roberto Valducci Formulazioni farmaceutiche solide orali a rilascio multifasicoph-dipendente.

Also Published As

Publication number Publication date
KR100859358B1 (ko) 2008-09-22
WO2003032952A1 (en) 2003-04-24
ATE371441T1 (de) 2007-09-15
CN100506234C (zh) 2009-07-01
NO335042B1 (no) 2014-09-01
DE60130270D1 (de) 2007-10-11
ES2288999T3 (es) 2008-02-01
JP4726414B2 (ja) 2011-07-20
DK1441700T3 (da) 2007-10-08
HK1068282A1 (en) 2005-04-29
DE60130270T2 (de) 2008-05-29
EP1441700A1 (en) 2004-08-04
MXPA04003506A (es) 2004-07-23
PT1441700E (pt) 2007-10-29
CN1558752A (zh) 2004-12-29
KR20040047906A (ko) 2004-06-05
IL161193A0 (en) 2004-08-31
IL161193A (en) 2010-05-31
CA2462905A1 (en) 2003-04-24
JP2005509619A (ja) 2005-04-14
CA2462905C (en) 2011-04-12
EP1441700B1 (en) 2007-08-29

Similar Documents

Publication Publication Date Title
BR9503386A (pt) Formulaçao farmacêutica comprimido dispersivel e processo para a fabricaçao de comprimidos dispersíveis contendo cloridrato de fluoxetina
NO20042011L (no) Fremgangsmate ved fremstilling av en farmasoytisk sammensetning omfattende 5-aminosalisylsyre for bruk ved behandling av ulcerativ kolitt og Crohns sykdom
NO20075046L (no) Gastroresistente farmasoytiske formuleringer inneholdende rifaximin
NO20053855L (no) 1-fenylalkankarboksylsyrederivater til behandling av neurodegenerative sykdommer.
DK1024794T3 (da) Fremgangsmåde til behandling af kapsler og törre, pulveriserede farmaceutiske formuleringer
HUP0204399A3 (en) Pteridine compounds for the treatment of psoriasis, process for their preparation, pharmaceutical compositions containing them and their use
TR200200716T2 (tr) Ketiyapin granülleri
HUP0302538A3 (en) 3,7-diazabicyclo[3.3.0]oczanes and their use in the treatment of cardiac arrhythmias, process for their preparation and pharmaceutical compositions containing them
HUP9700806A2 (hu) Tianeptin-nátriumsó nyújtott felszabadulását biztosító, szájon át beadható mátrix tabletta és eljárás előállítására
WO2000072823A8 (en) Preparations for the application of anti-inflammatory agents
MY137570A (en) Method for the preparation of a pharmaceutical composition comprising 5-aminosalicyclic acid for use in treatment of ulcerative colitis crohn's disease
HUP0401325A3 (en) Isoxazolopyridinones useful in the treatment of parkinson's disease, process for their preparation and pharmaceutical compositions containing the compounds
HUP9802897A3 (en) Optically active pyridyl-4h-1,2,4-oxadiazine derivatives, the use thereof in the treatment of vascular diseases and pharmaceutical composition containing the compound as active ingredient
SE0001916D0 (sv) Novel formulation
ATE305799T1 (de) Stabilisierte pharmazeutische zusammensetzungen und verfahren zu ihrer herstellung, mit einem antibiotikum und einem expektorans
HRPK20030006B1 (en) Pharmaceutical disinfective preparations on the basis of usnic acid sodium salt and medical plants and process for their obtaining
NO20031108L (no) Farmasöytisk preparat for behandling av hodepine, og fremgangsmåte for fremstilling av preparatet
ITRM990483A0 (it) Composizione per la prevenzione e cura delle disfunzioni e patologie renali di tipo tossico e funzionale.
PL368040A1 (en) Substituted 4-aminocyclohexanol derivatives
DK0538690T3 (da) Arylquinolyl-substituerede 1,4-dihydropyridin-dicarboxylsyrederivater, fremgangsmåde til deres fremstilling af deres anvendelse i lægemidler
IL152751A0 (en) Optically active 2-aminotetralin derivatives, the processes for the preparation thereof and the therapeutical use of pharmaceutical compositions containing them
Sadikov et al. Development and introduction of the novel domestic anthelmintic agent albendazole
PL369504A1 (en) Method for the preparation of a pharmaceutical composition comprising 5-aminosalicyclic acid for use in treatment of ulcerative colitis and crohn's disease
NZ532449A (en) Method for the preparation of a pharmaceutical composition comprising 5-aminosalicyclic acid for use in treatment of ulcerative colitis and Crohn's disease
HUP9802896A3 (en) Optically active piperidinoalkyl-4h-1,2,4-oxadiazine derivative, the use thereof in the treatment of vascular diseases and pharmaceutical composition containing the compound as active ingredient

Legal Events

Date Code Title Description
MK1K Patent expired